Giant Liver Hemangioma

EPIDEMIOLOGY & RISK PROFILE

- 20% of population affected most common benign liver tumor¹
- 30-50 years peak incidence²
- 3-5x more common in women than men³
- **2.5x** risk increase with pregnancy or hormone replacement therapy³
- >4-5 cm size at which symptoms often appear

Oral contraceptives and corticosteroids may accelerate growth, though not causative4

CLINICAL PRESENTATION

Symptomatic hemangiomas may cause:

- RUQ pain
- Abdominal distension
- Nausea
- **Jaundice**
- Peripheral edema

POTENTIAL COMPLICATIONS

If untreated, giant liver hemangiomas can result in:


- Compression of adjacent organs
- Consumptive coagulopathy (Kasabach-Merritt Syndrome)
- Intra-lesional thrombosis
- Congestive heart failure (high-flow lesions)
- Spontaneous or iatrogenic rupture

Although rupture is rare (1–4%), the mortality rate from hemorrhagic complications during surgery is 36%⁵

- Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors. J Clin Gastroenterol 2005;39:401–12
 Gandolfi L, Leo P, Solmi L, Vitelli E, Verros G, Colecchia A. Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut.
- history of hepatic International 1991;32(6):677–80.

 3. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 3. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 5. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 6. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 7. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Boaz M, Levine A, Shirin H. Hepatic
 8. Glinkova V, Shevah O, Shirin H. Hepatic
 8. Glinkova V, Shirin H. Hepatic
 8.
- 2004;Sig)(1352.
 Source: National Institute of Diabetes and Digestive and Kidney Diseases: LiverTox: Clinical and Research Information on Drug-Ind Liver Injury, Updated May 28, 2020.
 Ozden I, Ermer A, Alper A, Tunach, Bilge O, Tekant Y, et al. Long-term results of surgery for liver hemangiomas. Arch Surg. (2000)
- 135.978–81. 6. Angelo Amico et al. Giant hepatic hemangioma case report: When is it time for surgery? Annals of Medicine and Surgery Volume 55, October 2020, Pages 4-7.

 1. Herman P, Costa ML, Machado MA, et al. Management of hepatic hemangiomas: a 14-year experience. J Gastrointest Surg 2005; 953–859.
- Newhook TE, LaPar DJ, Lindberg JM, Bauer TW, Adams RB, Zaydfudim VM. Motbidily and mortalily of hepatectomy for benign liver tumors. Am J Surg. 2016;21t:102–8.
 Gao J, ke S, Ding XM, Zhou YM, Qian XJ, Sun WB. Radiofrequency
- abaquon for large repatit: hernangionias, linual experience ainu. Surgery, 2013;153:78–85. 10. Tak WY, Park SY, Jeon SW, et al. Ultrasonography-guided percutaneous radiofrequency ablation for treatment of a huge symptomatic hepatic cavernous hemangioma. J Clin Gastroent 2006;40:167–70.
- 2011:54:559-65.
- 2011;54:559-55.
 211;54:559-65.
 22.Niloofar Ayoobi Yazdi, ME et al. Percutaneous Sclerotherapy with Bleomycin and Ethiodized Oil: A Promising Treatment in Sympton Giant Liver Hemangioma. Radiology 2021; 301:464-471.



TREATMENT OPTIONS:

Bevacizumab (Anti-VEGF Therapy)

- Mixed results in case reports
- May reduce hemangioma volume in select patients

Interferon Alfa-2a

- Effectively used in pediatric vascular anomalies
- Limited evidence for adult hepatic hemangiomas

Radiation Therapy

Obsolete in most cases due to availability of safer, more effective options

Surgical Resection

- Historically, 57% of symptomatic or giant hemangiomas underwent surgery⁶
- Symptoms can persist post-resection⁵
- 30-day mortality for benign liver tumor resection approaches 1%8

Radiofrequency Ablation (RFA)

- Can achieve localized tumor shrinkage⁹
- Risks increase with tumor size and include: Hemolysis, hemoglobinuria, jaundice, renal impairment 10,11

Percutaneous Sclerotherapy

- Bleomycin + Ethiodized Oil
- Safe, image-guided, outpatient procedure
- Effective in reducing hemangioma size and relieving symptoms
- Pain scores reducing from 8.3 to 1.4
- 61% achieving complete relief, 31% partial relief at 12-month follow-up¹²

CONCLUSION

While most hepatic hemangiomas remain clinically silent, giant lesions can carry significant morbidity and warrant intervention when symptomatic or growing. Sclerotherapy is a highly effective alternative to surgery. Our providers are pioneers in this technique, our team welcomes provider inquiries.



NorthStarIR.com P: (952) 960-9399 F: (952) 206-6467

8401 Golden Valley Rd Suite 340 Golden Valley, MN 55427









